Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024

CRNX 10.16.2024

Full Press ReleaseSEC FilingsOur CRNX Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - Crinetics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
  • 01.10.2025 - Crinetics Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • 01.10.2025 - Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

  • 01.14.2025 - 8-K Current report
  • 01.14.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 4 Statement of changes in beneficial ownership of securities

SAN DIEGO,Oct. 16, 2024(GLOBE NEWSWIRE) --Crinetics Pharmaceuticals, Inc.(Nasdaq: CRNX) today announced that it will report third quarter 2024 financial results onTuesday, November 12, 2024after the market closes. Company management will host a conference call at4:30 p.m. ETto discuss financial results and provide a business update.

Conference Call & Webcast

Tuesday, November 12@4:30 p.m. ET
Domestic:1-800-579-2543
International:1-785-424-1789
Conference ID:CRNXQ3

Participants can use the dial-in numbers above OR access the call via live webcast on theEvents sectionof the Crinetics website. To ensure a timely connection, it is recommended that participants dial-in or register at least 15 minutes prior to the scheduled start of the call.

The webcast will be archived on the Investor Relations section ofwww.crinetics.com.

AboutCrinetics PharmaceuticalsCrinetics Pharmaceuticalsis a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist that has completed Phase 3 clinical development for acromegaly and is in Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

Investors:Gayathri DiwakarHead of Investor Relationsgdiwakar@crinetics.com(858) 345-6340

Media:Natalie BadilloHead of Corporate Communicationsnbadillo@crinetics.com(858) 345-6075

Primary Logo

Source: Crinetics Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com